{"id":"W4323033688","doi":"10.1016/s1470-2045(23)00052-9","title":"Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"Pfizer Canada; European Society for Medical Oncology; Merck Sharp and Dohme; Eisai; Bayer HealthCare; Seagen; Incyte; Ipsen; Clovis Oncology; PharmaMar; Ipsen Biopharmaceuticals; AstraZeneca Canada; Gilead Sciences; Mersana Therapeutics; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Bevacizumab; Pembrolizumab; Carboplatin; Chemotherapy; Placebo; Clinical endpoint; Internal medicine; Cervical cancer; Oncology; Cancer; Surgery; Clinical trial; Cisplatin; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002848035,0.0006019956,0.005362674,0.000284529,0.0002819516,0.00003220357,0.0004217479,0.0002443396,0.001328084],"category_scores_gemma":[0.0007898715,0.0002520236,0.0005257669,0.001490379,0.0004006643,0.00008885609,0.0000610704,0.000564547,0.0000203668],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009365904,"about_ca_system_score_gemma":0.005488957,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001627689,"about_ca_topic_score_gemma":0.007630446,"domain_scores_codex":[0.994571,0.001148754,0.001673224,0.0007629433,0.000770932,0.001073153],"domain_scores_gemma":[0.9926761,0.004376556,0.001387906,0.000710386,0.0003393447,0.000509676],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9765149,0.001822671,0.0001103725,0.001035658,0.005819661,0.00006567152,0.001906235,0.0001748213,0.00002173277,0.00006136944,0.001576752,0.0108901],"study_design_scores_gemma":[0.9387404,0.05193551,0.00005013071,0.0002708986,0.002271769,0.0001372589,0.001049528,0.00162807,0.00004608403,0.00003134484,0.003506273,0.0003327049],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.940223,0.00133389,0.0004132075,0.02816457,0.000674471,0.02773636,0.0004453326,0.000283079,0.000726029],"genre_scores_gemma":[0.973201,0.001672034,0.001023291,0.003069511,0.001304785,0.01314941,0.0002868999,0.0001525976,0.006140444],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05011284,"threshold_uncertainty_score":0.9999932,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2100095022740117,"score_gpt":0.4556659257109718,"score_spread":0.24565642343696,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}